Form 4: Zoetis EVP Acquires Phantom Stock Units

Zoetis Inc. Executive Vice President Keith Sarbaugh acquired 626.6723 phantom stock units through the company's supplemental savings plan.

Summary

• Keith Sarbaugh, Executive Vice President of Zoetis Inc., acquired 626.6723 phantom stock units on March 27, 2026.
• These units were acquired pursuant to the Zoetis Supplemental Savings Plan.
• Each phantom stock unit represents a fraction of a phantom share of Zoetis common stock, plus a small amount of cash-equivalent investments, typically around 5% of the total unit value.
• The value of each phantom stock unit is determined by reference to the market value of Zoetis common stock and the value of the cash-equivalent investments.
• The units are settled in cash following Sarbaugh's separation from service.
• Following this transaction, Sarbaugh beneficially owns a total of 1,874.4329 phantom stock units.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it represents a routine executive compensation transaction that aligns management's interests with shareholder value, without indicating any significant operational or financial changes.

Positives

• An executive acquiring phantom stock units through a supplemental savings plan indicates alignment of management's interests with shareholder value, as the units' value is directly tied to the company's common stock performance.

Risks

• The value of the phantom stock units is directly tied to the market value of Zoetis common stock, meaning a decline in ZTS stock price would reduce the value of these units.
• Zoetis may limit the timing, frequency, and permissibility of transfers from one investment fund to another within the supplemental savings plan at any time.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding the company's future performance, focusing solely on an executive's acquisition of phantom stock units.

Industry Context

StockSavvy.ai notes that executive participation in supplemental savings plans, particularly those tied to company equity, is a common practice across various industries, including the animal health and pharmaceutical sectors. Such plans aim to align executive incentives with long-term shareholder value creation. This specific transaction reflects a routine compensation and savings mechanism rather than a strategic industry move.

Comparison to Industry Standards

• This transaction is consistent with typical executive compensation and savings plans observed in large, publicly traded companies within the animal health and broader pharmaceutical industries.
• Companies like Elanco Animal Health (ELAN) or IDEXX Laboratories (IDXX) often utilize similar equity-linked deferred compensation structures to retain and incentivize key executives.
• The acquisition of phantom stock units, whose value is tied to the company's stock performance, aligns with best practices for executive incentive alignment.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of executive incentives with stock performance, as the value of the phantom units is tied to Zoetis's common stock.

Key Dates

Recommendation

This Form 4 filing reports a routine executive acquisition of phantom stock units through a company-sponsored savings plan. While it indicates alignment of executive interests with shareholder value, it does not provide new information that would warrant a change in investment recommendation. The transaction is part of standard compensation and does not reflect a significant change in the company's operational or financial outlook.

Keywords

Zoetis, ZTS, Form 4, Insider Transaction, Phantom Stock Units, Executive Compensation, Supplemental Savings Plan, Keith Sarbaugh